Interpretation of the updates of NCCN esophageal and esophagogastric junction cancers clinical practice guidelines in oncology (version 1.2025)
- VernacularTitle:《NCCN食管和食管胃结合部癌临床实践指南（2025 V1版）》主要更新点解读
- Author:
Yi WANG
1
;
Siyu CHEN
1
;
Weitong YIN
1
;
Jun WANG
1
Author Information
1. Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal cancer;
esophagogastric junction cancer;
National Comprehensive Cancer Network guideline;
interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(09):1225-1232
- CountryChina
- Language:Chinese
-
Abstract:
According to the latest GLOBOCAN data released in 2024, esophageal cancer ranks the 11th in global cancer incidence and represents the 7th leading cause of cancer-related mortality worldwide. In 2022, there were approximately 511000 newly diagnosed cases of esophageal cancer and 445000 deaths globally. On February 28, 2025, the National Comprehensive Cancer Network (NCCN) published updated clinical practice guidelines for esophageal and esophagogastric junction cancers (version 1.2025). This article provides a comprehensive analysis of the major diagnostic and therapeutic updates in the guidelines compared to the version 5.2024, encompassing key domains including screening stratification protocols, perioperative treatment optimization strategies, dynamic efficacy evaluation systems, molecular subtyping-guided therapeutic approaches, and immunotherapy expansion algorithms. The findings aim to provide references for esophageal cancer treatment in China.
